Fate Therapeutics, Inc.
2.44USD
-0.0600 (-2.40%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.26▲ | $-0.26 | 4 | 2 |
| Next quarter | $-0.27▼ | $-0.26 | 3 | 3 |
| Current year | $-1.02▲ | $-1.04 | 4 | 2 |
| Next year | $-0.97▼ | $-0.92 | 3 | 1 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.26 | $-0.25 | +0.01 (+2.6%) |
| 2026-03-31 | $-0.28 | $-0.26 | +0.02 (+5.5%) |
| 2025-12-31 | $-0.27 | $-0.27 | +0.00 (+0.5%) |
| 2025-09-30 | $-0.28 | $-0.27 | +0.01 (+4.3%) |
137 ratings from 28 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Piper Sandler | Reiterated | Overweight | $6 $8 | Aug 14, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $2.5 $3.5 | Aug 14, 2026 |
| Wedbush | Reiterated | Outperform | $7 | Aug 14, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $7 | Jun 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $5 $7 | May 4, 2026 |
| HC Wainwright & Co. | Upgraded from Neutral | Buy | $5 | Oct 31, 2025 |
| Wedbush | Upgraded from Neutral | Outperform | $5 $7 | Oct 27, 2025 |
| Needham | Reiterated | Hold | — | Oct 27, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $4 $2.5 | Aug 13, 2025 |
| Needham | Reiterated | Hold | — | Jun 12, 2025 |
| Barclays | Maintained | Overweight | $10 $2 | May 14, 2025 |
| Baird | Maintained | Neutral | $5 $4 | May 14, 2025 |
| Needham | Reiterated | Hold | — | May 14, 2025 |
| Stifel | Maintained | Hold | $5 $3 | Mar 6, 2025 |
| Wedbush | Reiterated | Neutral | $5 | Mar 6, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $5 $4 | Mar 6, 2025 |
| Needham | Reiterated | Hold | — | Mar 6, 2025 |
| Needham | Reiterated | Hold | — | Nov 19, 2024 |
| Needham | Reiterated | Hold | — | Nov 13, 2024 |
| HC Wainwright & Co. | Reiterated | Neutral | $5 | Aug 22, 2024 |
| Needham | Reiterated | Hold | — | Aug 14, 2024 |
| Piper Sandler | Upgraded from Neutral | Overweight | $4 $6 | Jun 17, 2024 |
| HC Wainwright & Co. | Maintained | Neutral | $7 $5 | May 16, 2024 |
| Canaccord Genuity | Maintained | Buy | $11 $9 | May 10, 2024 |
| BMO Capital | Maintained | Market Perform | $7 $6 | May 10, 2024 |
23 filings from 7 insiders · 3 buy / 4 sell over 6m
Officers and directors of FATE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TAHL CINDY ROfficer | Sell | 38.8k | $2.46 | $95k | Aug 4, 2026 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 43.9k | $2.46 | $108k | Aug 4, 2026 |
| TAHL CINDY ROfficer | Sell | 25.6k | $1.88 | $48k | May 20, 2026 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 28.9k | $1.88 | $54k | May 20, 2026 |
| TAHL CINDY ROfficer | Exercise | 166.7k | $1.05 | $208k | May 6, 2026 |
| EPSTEIN ROBERT SDirector | Exercise | 25.0k | $1.69 | $42k | May 5, 2026 |
| RASTETTER WILLIAM HDirector | Exercise | 25.0k | $1.69 | $42k | May 5, 2026 |
| TAHL CINDY ROfficer | Grant | 100.0k | — | — | Jan 15, 2026 |
| VALAMEHR BAHRAMChief Executive Officer | Grant | 335.0k | — | — | Jan 15, 2026 |
| ADAWI KAMALChief Financial Officer | Grant | 25.0k | — | — | Jan 15, 2026 |
| TAHL CINDY ROfficer | Sell | 10.6k | $1.06 | $11k | Jan 9, 2026 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 5.2k | $1.07 | $6k | Jan 9, 2026 |
| ADAWI KAMALChief Financial Officer | Grant | 75.0k | — | — | Oct 20, 2025 |
| TAHL CINDY ROfficer | Sell | 9.0k | $1.06 | $10k | Aug 4, 2025 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 14.5k | $1.06 | $15k | Aug 4, 2025 |
| TAHL CINDY ROfficer | Grant | 70.0k | — | — | Jan 15, 2025 |
| BRESSI JEROME CHARLESOfficer | Grant | 65.0k | — | — | Jan 15, 2025 |
| TAHL CINDY ROfficer | Sell | 5.7k | $1.55 | $9k | Jan 10, 2025 |
| VALAMEHR BAHRAMChief Executive Officer | Sell | 8.7k | $1.54 | $13k | Jan 10, 2025 |
| BRESSI JEROME CHARLESOfficer | Sell | 6.0k | $1.55 | $9k | Jan 10, 2025 |
No analyst notes on FATE yet.
Analyst Ratings
9 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 4 | 6 | 0 | 0 | Buy2.45 |
| 1 mo ago | 1 | 4 | 6 | 0 | 0 | Buy2.45 |
| 2 mo ago | 1 | 5 | 6 | 0 | 0 | Buy2.42 |
| 3 mo ago | 1 | 5 | 6 | 0 | 0 | Buy2.42 |